Aging is a gradual and irreversible pathophysiological process. It presents with declines in
tissue and cell functions and significant increases in the risks of various aging-related …

Many drugs that target amyloid-β (Aβ) in Alzheimer disease (AD) have failed to demonstrate
clinical efficacy. However, four anti-Aβ antibodies have been shown to mediate the removal …

Amyloid β protein (Aβ) is the main component of neuritic plaques in Alzheimer's disease
(AD), and its accumulation has been considered as the molecular driver of Alzheimer's …

Alzheimer's disease (AD) is the most prevalent form of age-related dementia in the world,
and its main pathological features consist of amyloid-β (Aβ) plaque deposits and …

Results from recent clinical trials of antibodies that target amyloid-β (Aβ) for Alzheimer's
disease have created excitement and have been heralded as corroboration of the amyloid …

Aducanumab is a monoclonal antibody selective for amyloid β (Aβ) aggregates. In June
2021, aducanumab became the first drug underlying the pathophysiology of Alzheimer's …

China's population has rapidly aged over the recent decades of social and economic
development as neurodegenerative disorders have proliferated, especially Alzheimer's …

The concept of immune privilege suggests that the central nervous system is isolated from
the immune system. However, recent studies have highlighted the borders of the central …

Alzheimer's disease (AD) is the most common cause for dementia worldwide. Until recently,
all approved treatments for AD were symptomatic and not disease modifying. On 7 June …

Objective To investigate the effects of monoclonal antibodies against Aβ on cognition,
function, amyloid PET and other biomarkers, as well as risk for amyloid-related imaging …